

PREVALENCE AND DETERMINANTS OF COMPLEMENTARY AND ALTERNATIVE  
MEDICINE USE IN SUBJECTS WITH HYPERTENSION IN A TERTIARY CENTRE IN  
SOUTH EAST NIGERIA

**Abstract**

**Objective:** To study the prevalence and determinants of the use of complementary and alternative medicine (CAM) in patients with hypertension (HTN).

**Method:** Two hundred and fifty patients visiting the medical outpatient Clinic at Enugu State University Teaching Hospital in Southeast Nigeria were interviewed. Information was obtained on the patients' demographics, type(s), duration, pattern and disclosure of CAM use, sources of recommendation and reasons for using CAM.

**Results:** The prevalence of CAM use was 4.4%. The most commonly used CAM was biologic-based therapy; bitter leaf (*Vernonia amigdalina*) (90.9%), Ginger (90.9%), garlic (72.7%), Cinnamon (45.5%), bitter kola (*Garcinia kola*) (36.4%), lemon grass (9.1%), green tea (9.1%), guava (9.1%) and mango leaves (9.1%). This was followed by manipulative and body-based (exercise and relaxation), and then spiritual method (fasting and prayer). Most subjects used CAM concurrently with orthodox medicine (63.6%), and neither knew the constituent of what they were taking (72.7%) nor revealed to their healthcare provider (HCP) that they were on CAM (81.8%). The most common reason for the non-disclosure is that the HCP will discourage them (66.7%). Most subjects used CAM to manage hypertension (54.5%).

**Conclusion:** A proportion of patients receiving orthodox medication for HTN also use CAM. A better treatment outcome would emanate from education of HCP and the general public on CAM use, legislation on the control of unwholesome and harmful use of CAM, and well-funded research on proven and potential CAM modalities for the benefit of humanity.

**KEY WORDS.** Hypertension, Complementary and alternative, medicine.

**INTRODUCTION:**

“Hypertension (HTN) is associated with a large global burden of cardiovascular disease (CVD) and premature death. In 2015, the estimated number of all-cause deaths that were associated with systolic blood pressure(BP)  $\geq 110$ –115 mmHg was 10.7 million (19.2% of all deaths) and with systolic BP  $\geq 140$  mm Hg was 7.8 million (14.0% of all deaths)” [1]. “Essential HTN, which is not curable, is the most frequent type of HTN in adults (95%) and is diagnosed when there is sustained elevation of BP at  $\geq 140/90$ mm Hg and when no etiology can be determined” [2, 3]. “Side effects of commonly used antihypertensives include dizziness, fatigue, headache, confusion, depressed mood, chest pain, difficulty breathing, constipation, diarrhoea, swelling in parts of the body, reduced sex drive, erectile dysfunction, persistent cough, increased frequency of urination, rash and difficulty sleeping” [4, 5] These side effects and the incurable nature of the ailment markedly reduce adherence to antihypertensive medications, with the attendant risk of increased cardiovascular morbidity and mortality [6, 7]. This has also encouraged hypertensive subjects to seek other seemingly safer and more effective treatment modalities of treatment.

“The frequency of utilization of complementary and alternative medicine(CAM) is increasing worldwide, and is well documented in both African and global populations to be between 20 – 80%” [8, 9]. “The National Institute of Health (NIH) classifies CAM into five major categories: *alternative medical systems* (e.g. traditional oriental medicine, acupuncture, Ayurveda, naturopathy, homeopathy, Native American healing, Tibetan medicine), *mind-body interventions* (meditation, hypnosis, dance, art and music therapy, spiritual healing, and prayer), *biologic – based therapies* (herbal medicine and dietary supplements, special diets, and orthomolecular medicine), *manipulative and body-based methods* (chiropractic, massage, the Feldenkrais method, other "body work" systems, and aspects of osteopathic medicine such as craniosacral work), and *energy therapies* (reiki, therapeutic touch, and other methods of affecting the "bioelectric field" of the body)” [10]. “There is limited data on the use of CAM among subjects with HTN in South East Nigeria. Previous studies on CAM use were done on cancer patients at a tertiary centre in Enugu” [11], another was a community-based study done among adult residents of 3 local governments in Enugu urban [12], while a recent one was on DM subjects [13]. This study sought to determine the prevalence and correlates of CAM use among subjects with HTN in a referral centre in Enugu, Southeast Nigeria.

## METHODS

This cross-sectional study was conducted at the Medical Outpatient clinic of the ESUT Teaching hospital, Parklane Enugu in South-East Nigeria between 1<sup>st</sup> November 2023 to 30<sup>th</sup> January 2024. Subjects with HTN who were aged 18 years and above were recruited for the study. “A validated interviewer-administered questionnaire was used to collect data from each participant. The questionnaire was developed from previous studies on CAM use” [14, 15]. “Sociodemographic data on age, gender, residence, tribe, marital status, educational background, occupation, income, and religion was obtained from each participant. The questionnaire also had a section on the type, form and method of preparation of CAM products consumed, co-administration of CAM with conventional medicine, reasons for CAM use, knowledge and duration of HTN, frequency of clinic visits, presence of complications of HTN, and disclosure of CAM use to health care providers. The questions were both open and closed ended. For participants who were not literate, the questionnaire was interpreted to them in the local dialect. CAM use was considered in this study as the use of it either as a complement or an alternative therapy according to the classification of CAM by the National Institute of Health [10]. All outpatients 18 years and older, diagnosed with HTN for one year or more, and who reported to the hospital for treatment were included. Participants were excluded if they were diagnosed with HTN for less than one year, were below the age of 18 years at the time of diagnosis, had incomplete data on their medical records, or had diabetes mellitus (DM)”. [50]

## RESULTS:

Table 1: Socio-demographic characteristics of the study participants

	Frequency	Percent
<b>Age</b>		
< 45 years	36	14.4
45-64 years	131	52.4
≥ 65	83	33.2
<b>Gender</b>		
Male	103	41.2
Female	147	58.8

---

<b><i>Religion</i></b>		
Christianity	249	99.6
Traditional	1	0.4
<b><i>Tribe</i></b>		
Igbo	249	99.6
Igala	1	0.4
<b><i>Residence</i></b>		
Urban	193	77.2
Rural	57	22.8
<b><i>Marital status</i></b>		
Single	21	8.4
Married	228	91.2
Separated	1	0.4
<b><i>Occupation</i></b>		
Business/trader	121	48.4
Civil servant	77	30.8
Artisan	15	6.0
Farmer	27	10.8
Unemployed	10	4.0
<b><i>Educational background</i></b>		
Illiterate	17	6.8
Primary	88	35.2
Secondary	82	32.8
Tertiary	63	25.2
<b><i>Monthly income</i></b>		
< 100000 naira	198	79.2
100000-500000 naira	52	20.8
>500000 naira	0	0.0
<b><i>Duration of hypertension</i></b>		
<1 year	0	0.0
1-5 years	164	65.6

---

5-10 years	62	24.8
>10 years	24	9.6
<b><i>Family history of hypertension</i></b>		
Yes	157	62.8
No	93	37.2
<b><i>Knowledge of hypertension</i></b>		
Spiritual problem	12	4.8
Preventable	210	84.0
Curable	181	72.4
Stress	205	82.0
Obesity	49	19.6
Poor sleep	178	71.2
Runs in the family	194	77.6
High salt intake	107	42.8
Bad luck	7	2.8
Poison	3	1.2

Table 1 shows that more than half of the study participants were in the middle age and were female. The participants were predominantly Christians, of the Igbo tribe extraction and were resident in urban area. Most were married, and about half were businessmen/women while about a third were civil servants. About a third of the study participants comprised of people with secondary and primary education while a quarter had tertiary education. About two thirds of the respondents earned less than 100,000 Naira, had duration of HTN of 1 to 5 years and a positive family history of HTN. Majority of the patients perceive hypertension as preventable, curable, stress-induced, associated with poor sleep and familial.

Table 2: Use of CAM

	Frequency	Percent
<b><i>Currently on CAM</i></b>		
Yes	11	4.4
No	239	95.6

---

<b><i>CAM duration</i></b>		
<1 year	5	45.5
1-2 years	3	27.3
2-5 years	1	9.1
>5 years	2	18.2
<b><i>Biologic-based therapy (BBT)</i></b>		
Lemon grass (Cymbopogon)	1	9.1
Bitter leaf (Vernonia amygdalina)	10	90.9
Ginger	10	90.9
Garlic	8	72.7
Cinnamon	5	45.5
Bitter kola (Garcinia kola)	4	36.4
Green tea	1	9.1
Guava leaves	1	9.1
Mango leaves	1	9.1
<b><i>Method of preparation</i></b>		
Heating	2	18.2
Boiling	3	27.3
Cooking	1	9.1
Chewing	1	9.1
<b><i>Spiritual method</i></b>		
Fasting	2	18.2
Prayer	2	18.2
Holy water	0	0.0
<b><i>Manipulative and body based</i></b>		
Exercise	5	45.5
Relaxation	6	54.5
Massage	0	0.0
<b><i>Who introduced you to CAM?</i></b>		
Friend	6	54.5
Media	2	18.2

---

CAM practitioner	1	9.1
<b><i>CAM use before diagnosis of HTN</i></b>		
Yes	2	18.2
No	9	81.8
<b><i>Do you know the constituent of the CAM you are using?</i></b>		
Yes	3	27.3
No	8	72.7
<b><i>Pattern of CAM use</i></b>		
Concurrently with conventional medicines	7	63.6
Alternative use	3	27.3
Stopped conventional medication when using CAM	1	9.1
<b><i>Reasons for use of CAM</i></b>		
To manage hypertension	6	54.5
To manage complications	2	18.2
To reduce symptoms	2	18.2
To maintain body health	4	36.4
Improve energy	2	18.2
Emotional well being	1	9.1
To reduce expenditure	1	9.1
<b><i>Clinic visit while on CAM</i></b>		
No	3	27.3
Yes	8	72.7
<b><i>Disclosure to your HCP</i></b>		
Yes	2	18.2
No	9	81.8
<b><i>Reason for non-disclosure</i></b>		
HCP did not ask	2	22.2
Never thought of it	1	11.1
HCP will discourage me	6	66.7

Table 2 shows that the prevalence of Cam use among hypertensive patients is 4.4%. CAM duration is less than a year for about half of the patients, and 1 to 2 years for about a quarter. The type of CAM mostly taken by the patients are bitter leaf, ginger, garlic and cinnamon. Most of the CAM users reported that they were introduced to it by their friends, and neither used it before the diagnosis of hypertension, nor knew the constituent of the CAM they are taking. About two thirds of the subjects used CAM concurrently with conventional medicines, while less than a third used it alternatively. Their major reasons for use of CAM included to manage hypertension in about half of the subjects while about a third used it to maintain body health. Poor clinic visits while on CAM were reported by about three quarters of the patients, while most subjects did not disclose that they were on CAM, with about two thirds not disclosing because of fear of discouragement by the HCP.

Table 3: Association between Socio-demographic factors of the hypertensive patients and CAM use

	Currently on CAM use		P value	OR	95% C.I for OR
	Yes	No			
<b><i>Age</i></b>					
<45 years	2 (5.6)	34 (94.4)	0.716	1.340	0.277 – 6.470
≥45 years	9 (4.2)	205 (95.8)			
<b><i>Gender</i></b>					
Male	1 (1.0)	102 (99.0)	0.058	0.134	0.017 – 1.066
Female	10 (6.8)	137 (93.2)			
<b><i>Residence</i></b>					
Urban	8 (4.1)	185 (95.9)	0.718	0.778	0.200 – 3.036
Rural	3 (5.3)	54 (94.7)			
<b><i>Marital status</i></b>					
Single/separated	2 (9.1)	20 (90.9)	0.276	2.433	0.492 – 12.042
Married	9 (3.9)	219 (96.1)			
<b><i>Occupation</i></b>					
Employed	10 (4.2)	230 (95.8)	0.395	0.391	0.045 – 3.396

Unemployed	1 (10.0)	9 (90.0)			
<b><i>Educational level</i></b>					
None/primary	2 (1.9)	103 (98.1)	0.122	0.293	0.062 – 1.387
Post primary	9 (6.2)	136 (93.8)			
<b><i>Income</i></b>					
<100,000 naira	6 (3.0)	192 (97.0)	0.051	0.294	0.086 – 1.004
≥ 100,000 naira	5 (9.6)	47 (90.4)			
<b><i>HTN duration</i></b>					
≤5 years	10 (4.4)	216 (95.6)	0.953	1.065	0.130 – 8.696
>5 years	1 (4.2)	23 (95.8)			

Table 3 shows no significant association between Socio-demographic factors of the hypertensive patients and CAM use ( $p > 0.05$ ).

## DISCUSSION:

More than half of the participants in this study were female, buttressing the fact females have better health-seeking habits than men [16]. Apart from a considerable number who feel that hypertension is curable, and the few who associated it with spiritual problem, bad luck and poison, our patients generally had good knowledge of HTN regarding its aetiology and risk factors. The prevalence of CAM use among hypertensive patients in this study was 4.4%. A multicentre prospective study in Lagos, South-west Nigeria on 1,325 hypertensive patients found that 21% of the subjects feel strongly that they will achieve better blood pressure control and possible cure using CAM [17]. Another study done on 500 ambulatory hypertensive patients in the clinic of a secondary health care facility in Maiduguri, Northern Nigeria, found that 24% of the respondents were using herbal medicines [18]. A community-based study on 440 hypertensive subjects in Ibadan, South-west Nigeria found that 29% used CAM in the management of their hypertension [14], while another study carried out among 225 subjects in the hypertension clinic of a University Teaching Hospital in Lagos, South-west Nigeria found that the prevalence of

CAM use was 39.1% [19]. In other countries in Africa, other researchers also found varying prevalence; Ghana 19.5% [20], South Africa 21% [21], Morocco 80% [22], Ethiopia 67.8% [23] and 33.5% in Kenya [24]. Beyond Africa, the prevalence was 40% in USA [25], 48.5% in Australia [26], 85.7% in Palestine [27] and 49.8% in India [28]. The varying differences in the prevalence could have been from tribal, cultural, ethnic, regional, racial, religious, socioeconomic differences between subjects, as well as differences in methodology among researchers. Other possible contributors to this variation include the different degrees of CAM regulation in different countries and the incorporation of CAM in orthodox medical practice and training, as well as insurance cover for CAM by some countries [29, 30, 31]. The very low prevalence found in this study could have been from the fact that, like in previous studies, most patients do not reveal to their healthcare provider (HCP) that they were on CAM [13, 18, 20, 27, 28]. The commonest reason for the non-disclosure in this study is the fear of discouragement, followed by the lack of enquiry by the attending HCP. The whole situation could have been worsened by the fact that this study was hospital-based and the data was collected by doctors. Other researchers also found similar reasons for this non-disclosure by subjects [13, 20, 32].

The most commonly used CAM in this study is biologic-based therapy comprising bitter leaf (*Vernonia amigdalina*), ginger, garlic, cinnamon, bitter kola (*Garcinia kola*), lemon grass, green tea, guava and mango leaves which are all known to reduce blood pressure [33, 34, 35, 36, 37, 38, 39, 40]. Most herbal medicines control and reduce HTN by exerting antioxidant, anti-inflammatory, and anti-apoptosis properties, stimulating the endothelial nitric oxide synthase-nitric oxide (eNOS-NO) signaling pathway, suppressing endothelial permeability, and activating angiogenesis [41]. Specifically, the components of garlic inhibit angiotensin converting enzyme (ACE) activity, diminish Angiotensin II-induced vasoconstrictor responses, prevent vascular smooth muscle cell (VSMCs) proliferation in smooth muscles, antagonize endothelin-1 prompted vasoconstriction, and inhibit the stimulation of nuclear factor-kappa B (NF-Kb) [35]. Moreover, ginger is considered to be a new Angiotensin II type 1 receptor antagonist while the antihypertensive effects of lemon grass has been ascribed to citral, its active phytochemical compound [36, 40].

However, it should be borne in mind that the use of CAM is also fraught with many problems including drug-to-drug interactions, side effects, dosing, limited knowledge of the various

constituents of each CAM, and the possibility of causing further complications in the subjects taking them [13]. This problem is further compounded by weak regulation of the production, distribution, and use of non-orthodox remedies in Nigeria [42]. The second most common CAM in this study is manipulative and body-based therapy which is composed of relaxation and exercise. Exercise and relaxation are established to be effective in the prevention, treatment, and control of HTH [43, 44]. Bringing up the rear in CAM modalities used by subjects in this study is spiritual methods (fasting and prayer). Mind/body interventions such as prayer and fasting were utilised by many CAM users in this study, which is consistent with similar findings in studies conducted in Ethiopia [23, 45] and in the USA, especially among the non-white population [46]. This modality of CAM is cheap and easy to undertake, and may be effective considering the fact that Wellness encompasses 8 mutually interdependent dimensions: physical, intellectual, emotional, social, spiritual, vocational, financial, and environmental [47]. Holistic “wellness” entails attending to all the aforementioned factors, without which one’s health may be hampered in one way or the other.

In this study, the use of CAM was neither associated with socio-demographic factors nor with the duration of hypertension. This was similar to the findings by other researchers in Nigeria and India [19, 48]. However, a community-based study among 440 subjects in Ibadan Southwest Nigeria found that gender, marital status and occupation were significantly associated with CAM use [14]. Similarly, a study on 450 subjects done in a general hospital in Debre Tabor town, Northwest Ethiopia found that age, residence, educational and income status, duration and family history of HTN positively correlated with CAM use [23]. Also, a population-based study done on 9,187 subjects in California USA found that age, gender, race, ethnicity and income associated with the use of CAM [49]. The differences with our studies could have been from regional, tribal, ethnic, racial and socioeconomic factors, as well as differences in methodology by other researchers.

## **CONCLUSION:**

1. The prevalence of CAM use by hypertensive subjects in this centre is relatively low.
2. Most subjects use CAM concurrently with orthodox medication.
3. Most participants in this study do not disclose the fact that they use CAM to their HCP, and were oblivious of the constituents of the CAM they were taking.

## **RECOMMENDATIONS:**

- I. Awareness programs targeting HCPs and patients on the use of CAM should be created to educate them on the various aspects of this treatment modality. This will ensure that the HCPs have the requisite knowledge about CAM for more effective communication with patients.
2. Guidelines should be created and regulatory bodies empowered to check the unwarranted and harmful use of CAM.
3. Research on potential and proven beneficial medicinal plants should be funded by the government and various organizations to explore different mechanisms of favourable metabolic effects these CAMs may harbor.

### **Consent and Ethical Approval:**

Informed consent was obtained from each study participant who agreed to participate after the study had been explained in English or local dialect. The approval for the study was obtained from the ethics and research committee of the hospital.

## **CONFLICT OF INTEREST:**

We declare no conflict of interest.

## **AUTHORS' CONTRIBUTIONS:**

- MC Abonyi – conception, design of research and manuscript writing
- TE Ugwu – data collection/cleaning, data analysis and manuscript editing
- CM Ezeude – Literature search
- CV Ugwueze – manuscript writing
- N Okoro – manuscript writing and editing
- CC Eze – literature search and manuscript writing/editing

- UC Okechukwu – data collection and interpretation
- FC Ekochin – literature review and manuscript writing.
- C Bozimo – literature search and manuscript writing/editing
- K Akhidue – literature search and editing of the manuscript
- B Nwatu – Final review and certification of the manuscript
  - EE Young- Final review and certification of the manuscript

## REFERENCES

1. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. *Nat Rev Nephrol.* 2020; **16**(4): 223-237. doi: 10.1038/s41581-019-0244-2.
2. Lenfant C, Chobanian AV, Jones DW, Roccella EJ; Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. *Hypertension.* 2003; **41**(6): 1178-9. doi: 10.1161/01.HYP.0000075790.33892.AE. Epub 2003 May 19. PMID: 12756222.
3. Iqbal AM, Jamal SF. Essential Hypertension. 2023 Jul 20. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. PMID: 30969681
4. Tedla YG, Bautista LE. Drug Side Effect Symptoms and Adherence to Antihypertensive Medication. *Am J Hypertens.* 2016; **29**(6): 772-9. doi: 10.1093/ajh/hpv185. Epub 2015 Dec 7. PMID: 26643686; PMCID: PMC5863783.
5. Kretchy IA, Owusu-Daaku FT, Danquah SA, Asampong E. A psychosocial perspective of medication side effects, experiences, coping approaches and implications for adherence in hypertension management. *Clin Hypertens.* 2015; **21**: 19. doi: 10.1186/s40885-015-0028-3. PMID: 26893929; PMCID: PMC4750803.
6. Hamrahian SM, Maarouf OH, Fülöp T. A Critical Review of Medication Adherence in Hypertension: Barriers and Facilitators Clinicians Should Consider. *Patient Prefer Adherence.* 2022 Oct 7;16:2749-2757. doi: 10.2147/PPA.S368784. PMID: 36237983; PMCID: PMC9552797.

7. Cohen JS. Adverse Drug Effects, Compliance, and Initial Doses of Antihypertensive Drugs Recommended by the Joint National Committee vs the Physicians' Desk Reference. *Arch Intern Med.* 2001; **161(6)**: 880–885. doi:10.1001/archinte.161.6.880
8. Tangkiatkumjai M, Boardman H, Walker DM. Potential factors that influence usage of complementary and alternative medicine worldwide: a systematic review. *BMC Complement Med Ther* 2020; **20**: 363. <https://doi.org/10.1186/s12906-020-03157-2>
9. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States. Prevalence, costs, and patterns of use. *N Engl J Med.* 1993; **328(4)**: 246-52. doi: 10.1056/NEJM199301283280406. PMID: 8418405.
10. Hughes EF, Jacobs BP, Berman BM: Complementary and alternative medicine. *Current Medical Diagnosis and Treatment.* Edited by: Tierney LM, McPhee SJ, Papadakis MA. 2005, New York, McGraw-Hill, 1696-1719.
11. Ezeome ER, Anarado AN. Use of complementary and alternative medicine by cancer patients at the University of Nigeria Teaching Hospital, Enugu, Nigeria. *BMC complementary and alternative medicine.* 2007; **7(1)**: 1-8.
12. Okoronkwo I, Onyia-pat J, Okpala P, Agbo M, Ndu A, "Patterns of Complementary and Alternative Medicine Use, Perceived Benefits, and Adverse Effects among Adult Users in Enugu Urban, Southeast Nigeria", *Evidence-Based Complementary and Alternative Medicine*, vol. 2014, Article ID 239372, 6 pages, 2014. <https://doi.org/10.1155/2014/239372>
13. Abonyi MC, Ezeude CM, Ugwueze VC, Nwatu CB, Nkpozi MO, Young EE. Prevalence and Determinants of Complementary and Alternative Medicine (CAM) Use Among Subjects with Diabetes Mellitus (DM) in a Tertiary Institution in South East Nigeria. *JDDT* 2024; **13(12)**: 15-1.
14. Osamor PE, Owumi BE Complementary and alternative medicine in the management of hypertension in an urban Nigerian community. *BMC Complement Altern Med* 2010; **10**, 36. <https://doi.org/10.1186/1472-6882-10-36>
15. Liwa AC, Smart LR, Frumkin A, Epstein HA, Fitzgerald DW, Peck RN. Traditional herbal medicine use among hypertensive patients in sub-Saharan Africa: a systematic review. *Curr*

- Hypertens Rep. 2014; **16(6)**: 437. doi: 10.1007/s11906-014-0437-9. PMID: 24764197; PMCID: PMC4076776.
16. Thompson AE, Anisimowicz Y, Miedema B, Hogg W, Wodchis WP, Aubrey-Bassler K. The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC study. *BMC Fam Pract* 2016; **17**, 38.  
<https://doi.org/10.1186/s12875-016-0440-0>
  17. Oke DA, Bandele EO. Misconceptions of hypertension. *J Natl Med Assoc.* 2004; **96(9)**: 1221-4. PMID: 15481752; PMCID: PMC2568468.
  18. Olisa NS, Oyelola FT. Evaluation of use of herbal medicines among ambulatory hypertensive patients attending a secondary health care facility in Nigeria. *Int J Pharm Pract.* 2009; **17(2)**: 101-5. PMID: 20214258.
  19. Amira OC, Okubadejo NU. Frequency of complementary and alternative medicine utilization in hypertensive patients attending an urban tertiary care centre in Nigeria. *BMC Complement Altern Med.* 2007; **7**: 30. doi: 10.1186/1472-6882-7-30. PMID: 17903257; PMCID: PMC2045097
  20. Kretchy IA, Owusu-Daaku F, Danquah S. Patterns and determinants of the use of complementary and alternative medicine: a cross-sectional study of hypertensive patients in Ghana. *BMC Complementary and Alternative Medicine.* 2014; **14**, article 44 doi: 10.1186/1472-6882-14-44.
  21. Hughes GD, Aboyade OM, Clark BL, Puoane TR. The prevalence of traditional herbal medicine use among hypertensives living in South African communities. *BMC Complementary and Alternative Medicine.* 2013; **13**, article 38 doi: 10.1186/1472-6882-13-38
  22. Eddouks M, Maghrani M, Lemhadri A, Ouahidi ML, Jouad H. Ethnopharmacological survey of medicinal plants used for the treatment of diabetes mellitus, hypertension and cardiac diseases in the south-east region of Morocco. *Journal of Ethnopharmacology.* 2002; **82(2-3)**: 97–103. doi: 10.1016/s0378-8741(02)00164-2.
  23. Kifle ZD, Yimenu DK, Kidanu BB. Complementary and alternative medicine use and its associated factors among hypertensive patients in Debre Tabor General Hospital, Ethiopia. *Metabol Open.* 2021; **12**: 100132. doi: 10.1016/j.metop.2021.100132. PMID: 34632358; PMCID: PMC8493576.

24. Peninah Jelagat K. Prevalence and factors associated with complementary and alternative medicine use among patients with hypertension in Turbo, Kenya. Moi University Open Access Repository.2019 <http://ir.mu.ac.ke:8080/jspui/handle/123456789/2740>
25. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. *JAMA*. 1998; **280(18)**: 1569-75. doi: 10.1001/jama.280.18.1569. PMID: 9820257
26. MacLennan AH, Wilson DH, Taylor AW. Prevalence and cost of alternative medicine in Australia. *The Lancet*. 1996; **347(9001)**: 569–573. doi: 10.1016/s0140-6736(96)91271-4.
27. Ali-Shtayeh MS, Jamous RM, Jamous RM, Salameh NMY Complementary and alternative medicine (CAM) use among hypertensive patients in Palestine. *Complementary Therapies in Clinical Practice*. 2013; **19(4)**: 256–263. doi: 10.1016/j.ctcp.2013.09.001.
28. Nailwal D, B VR, Gupta A. Patterns and predictors of complementary and alternative medicine use in people presenting with the non-communicable disease in an urban health facility, North India. *J Public Health Res* 2021; **10**: 2109
29. Marstedt G, Moebus S. InanspruchnahmealternativerMethoden in der medizin. Gesundheitsberichterstattung des Bundes. Berlin: Robert Koch Institut, 2002, pp. 7.
30. Klein SD, Torchetti L, Frei-Erb M, Wolf U. Usage of Complementary Medicine in Switzerland: Results of the Swiss Health Survey 2012 and Development Since 2007. *PLoS One*. 2015; **10(10)**: e0141985. doi: 10.1371/journal.pone.0141985. Erratum in: *PLoS One*. 2015;10(12):e0144676. PMID: 26513370; PMCID: PMC4626041.
31. Horneber M, Bueschel G, Dennert G, Less D, Ritter E, Zwahlen M. How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis. *Integr Cancer Ther*. 2012; **11(3)**: 187-203. doi: 10.1177/1534735411423920. Epub 2011 Oct 21. PMID: 22019489
32. Foley H, Steel A, Cramer H, Wardle J, Adam J. Disclosure of complementary medicine use to medical providers: a systematic review and meta-analysis. *Sci Rep* 2019; **9**: 1573. <https://doi.org/10.1038/s41598-018-38279-8>
33. Edo GI, Samuel PO, Jikah AN, Onoharigho FO, Idu LI, Obasohan P et al Biological and bioactive components of bitter leaf (*Vernonia amygdalina* leaf): Insight on health and nutritional benefits. A review, *Food Chemistry Advances*, Volume 3, 2023, 100488,ISSN 2772-753X, <https://doi.org/10.1016/j.focha.2023.100488>.

34. Shirzad F, Morovatdar N, Rezaee R, Tsarouhas K, Abdollahi Moghadam A. Cinnamon effects on blood pressure and metabolic profile: A double-blind, randomized, placebo-controlled trial in patients with stage 1 hypertension. *Avicenna J Phytomed.* 2021; **11(1)**: 91-100. PMID: 33628723; PMCID: PMC7885002.
35. Ried K. Garlic lowers blood pressure in hypertensive subjects, improves arterial stiffness and gut microbiota: A review and meta-analysis. *Exp Ther Med.* 2020; **19(2)**: 1472-1478. doi: 10.3892/etm.2019.8374. Epub 2019 Dec 27. PMID: 32010325; PMCID: PMC6966103
36. Hasani H, Arab A, Hadi A, Pourmasoumi M, Ghavami A, Miraghajani M. Does ginger supplementation lower blood pressure? A systematic review and meta-analysis of clinical trials. *Phytother Res.* 2019; **33(6)**: 1639-1647. doi: 10.1002/ptr.6362. Epub 2019 Apr 11. PMID: 30972845.
37. Chitra Devi R, Sim SM, Ismail R. Effect of *Cymbopogon citratus* and Citral on Vascular Smooth Muscle of the Isolated Thoracic Rat Aorta. *Evid Based Complement Alternat Med.* 2012; **2012**: 539475. doi: 10.1155/2012/539475.
38. Peng X, Zhou R, Wang B, Yu X, Yang X, Liu K. et al. Effect of green tea consumption on blood pressure: a meta-analysis of 13 randomized controlled trials. *Sci Rep.* 2014; **4**: 6251. doi: 10.1038/srep06251
39. Braga DC, Gomes PM, Carlos Batista MA, Souza JA, Almeida Bastos JC, Rodrigues-das-Dôres RG et al Effects of *Psidium guajava* L. leaves extract on blood pressure control and IL-10 production in salt-dependent hypertensive rats, *Biomedicine & Pharmacotherapy*, Volume 155, 2022, 113796, ISSN 0753-3322, <https://doi.org/10.1016/j.biopha.2022.113796>.
40. Silva H, Bárbara R. Exploring the Anti-Hypertensive Potential of Lemongrass-A Comprehensive Review. *Biology (Basel).* 2022; **11(10)**: 1382. doi: 10.3390/biology11101382. PMID: 36290288; PMCID: PMC9598547
41. Kamyab R, Namdar H, Torbati M, Ghojzadeh M, Araj-Khodaei M, Fazljou SMB. Medicinal Plants in the Treatment of Hypertension: A Review. *Adv Pharm Bull.* 2021; **11(4)**: 601-617. doi: 10.34172/apb.2021.090. Epub 2020 Nov 1. PMID: 34888207; PMCID: PMC8642800
42. Li S, Odedina S, Agwai I, Ojengbede O, Huo D, Olopade OI. Traditional medicine usage among adult women in Ibadan, Nigeria: a cross-sectional study. *BMC Complement Med Ther.* 2020; **20(1)**: 93.

43. Santaella DF, Araújo EA, Ortega KC, Tinucci T, Mion D Jr, Negrão CE, de Moraes Forjaz CL. Aftereffects of exercise and relaxation on blood pressure. *Clin J Sport Med.* 2006; **16(4)**: 341-7. doi: 10.1097/00042752-200607000-00010. PMID: 16858219.
44. Pescatello LS, Franklin BA, Fagard R, Farquhar WB, Kelley GA, Ray CA; American College of Sports Medicine. American College of Sports Medicine position stand. Exercise and hypertension. *Med Sci Sports Exerc.* 2004; **36(3)**: 533-53. doi: 10.1249/01.mss.0000115224.88514.3a. PMID: 15076798.
45. Asfaw Erku D, Basazn Mekuria A. Prevalence and Correlates of Complementary and Alternative Medicine Use among Hypertensive Patients in Gondar Town, Ethiopia. *Evid Based Complement Alternat Med.* 2016; **2016**: 6987636. doi: 10.1155/2016/6987636. Epub 2016 Oct 23. PMID: 27843480; PMCID: PMC5097805.
46. Robles B, Upchurch DM, Kuo T. Comparing Complementary and Alternative Medicine Use with or without Including Prayer as a Modality in a Local and Diverse United States Jurisdiction. *Front Public Health.* 2017; **5**: 56. doi: 10.3389/fpubh.2017.00056. PMID: 28377918; PMCID: PMC5359242
47. Stoewen DL. Dimensions of wellness: Change your habits, change your life. *Can Vet J.* 2017; **58(8)**: 861-862. PMID: 28761196; PMCID: PMC5508938.
48. Singh V, Raidoo DM, Harries CS. The prevalence, patterns of usage and people's attitude towards complementary and alternative medicine (CAM) among the Indian community in Chatsworth, South Africa. *BMC Complement Altern Med.* 2004; **4**: 3. doi: 10.1186/1472-6882-4-3. PMID: 15018622; PMCID: PMC356921
49. Goldstein MS, Brown ER, Ballard-Barbash R, Morgenstern H, Bastani R, Lee J, Gatto N, Amba A. The use of complementary and alternative medicine among california adults with and without cancer. *Evid Based Complement Alternat Med.* 2005; **2(4)**: 557-65. doi: 10.1093/ecam/neh138. Epub 2005 Oct 25. PMID: 16322814; PMCID: PMC1297511.
50. Abonyi MC, Ezeude CM, Ugwueze VC, Nwatu CB, Nkpozi MO, Young EE. Prevalence and Determinants of Complementary and Alternative Medicine (CAM) Use Among Subjects with Diabetes Mellitus (DM) in a Tertiary Institution in South East Nigeria. *Journal of Drug Delivery and Therapeutics.* 2023 Dec 15;13(12):15-21.

